Knockdown of HCG18 Inhibits Cell Viability, Migration and Invasion in Pediatric Osteosarcoma by Targeting miR-188-5p/FOXC1 Axis
- PMID: 34041718
- DOI: 10.1007/s12033-021-00343-6
Knockdown of HCG18 Inhibits Cell Viability, Migration and Invasion in Pediatric Osteosarcoma by Targeting miR-188-5p/FOXC1 Axis
Abstract
Understanding the underlying mechanisms of pediatric osteosarcoma (OS) migration and invasion is important for prognosis and treatment. We tried to measure the expression of long non-coding RNA HLA complex group 18 (HCG18) in OS and reveal its function in the malignant behaviors of OS cells. This study detected the expression of HCG18, miR-188-5p and forkhead box C1 (FOXC1) in OS tissues and cell lines by quantitative real-time PCR (qRT-PCR). The relevance between miR-188-5p and HCG18 or FOXC1 was affirmed by dual-luciferase reporter (DLR) assay. Cell viability was analyzed by MTT assay. Transwell assay was utilized to test cell invasion and migration. FOXC1 protein expression was detected by western blot. HCG18 expression was elevated in OS tissues, and enhanced HCG18 expression was related to metastasis. HCG18 silencing repressed the viability, migration and invasion of OS cells. Moreover, HCG18 interacted with miR-188-5p. MiR-188-5p up-regulation repressed cell viability, invasion and migration in OS cells. FOXC1, a known target of miR-188-5p, was negatively modulated by miR-188-5p. Furthermore, miR-188-5p inhibition or FOXC1 over-expression partially abolished the reduced of cell viability, invasion and migration mediated by HCG18 silencing in OS cell lines. This study revealed that HCG18 knockdown repressed the viability, invasion and migration of OS cells by targeting miR-188-5p and regulating FOXC1 expression. Thus, HCG18/ miR-188-5p/FOX may be a hopeful target for OS therapy.
Keywords: Forkhead box C1; HLA complex group 18; Invasion and migration; Osteosarcoma; miR-188-5p.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
LncRNA HCG18 Promotes Osteosarcoma Cells Proliferation, Migration, and Invasion in by Regulating miR-34a/RUNX2 Pathway.Biochem Genet. 2023 Jun;61(3):1035-1049. doi: 10.1007/s10528-022-10294-5. Epub 2022 Nov 19. Biochem Genet. 2023. PMID: 36401685
-
miR-106a-5p Suppresses the Proliferation, Migration, and Invasion of Osteosarcoma Cells by Targeting HMGA2.DNA Cell Biol. 2016 Sep;35(9):506-20. doi: 10.1089/dna.2015.3121. Epub 2016 Jul 6. DNA Cell Biol. 2016. Retraction in: DNA Cell Biol. 2020 Oct;39(10):1912. doi: 10.1089/dna.2015.3121.retract. PMID: 27383537 Retracted.
-
Up-regulation of microRNA-491-5p suppresses cell proliferation and promotes apoptosis by targeting FOXP4 in human osteosarcoma.Cell Prolif. 2017 Feb;50(1):e12308. doi: 10.1111/cpr.12308. Epub 2016 Oct 5. Cell Prolif. 2017. PMID: 27704627 Free PMC article.
-
Mir-34a: a regulatory hub with versatile functions that controls osteosarcoma networks.Cell Cycle. 2022 Oct;21(20):2121-2131. doi: 10.1080/15384101.2022.2087755. Epub 2022 Jun 14. Cell Cycle. 2022. PMID: 35699451 Free PMC article. Review.
-
MicroRNA-143 expression inhibits the growth and the invasion of osteosarcoma.J Orthop Surg Res. 2022 Apr 13;17(1):236. doi: 10.1186/s13018-022-03127-z. J Orthop Surg Res. 2022. PMID: 35418302 Free PMC article. Review.
Cited by
-
Osteosarcoma in a ceRNET perspective.J Biomed Sci. 2024 Jun 5;31(1):59. doi: 10.1186/s12929-024-01049-y. J Biomed Sci. 2024. PMID: 38835012 Free PMC article. Review.
-
The role of long non-coding RNA HCG18 in cancer.Clin Transl Oncol. 2023 Mar;25(3):611-619. doi: 10.1007/s12094-022-02992-8. Epub 2022 Nov 8. Clin Transl Oncol. 2023. PMID: 36346572 Review.
-
Therapeutically Targeting Cancers That Overexpress FOXC1: A Transcriptional Driver of Cell Plasticity, Partial EMT, and Cancer Metastasis.Front Oncol. 2021 Sep 3;11:721959. doi: 10.3389/fonc.2021.721959. eCollection 2021. Front Oncol. 2021. PMID: 34540690 Free PMC article. Review.
-
The regulatory role of LncRNA HCG18 in various cancers.J Mol Med (Berl). 2023 Apr;101(4):351-360. doi: 10.1007/s00109-023-02297-5. Epub 2023 Mar 6. J Mol Med (Berl). 2023. PMID: 36872315 Review.
References
-
- Sissons, H. A. (1976). The WHO classification of bone tumors. Recent Results in Cancer Research Fortschritte der Krebsforschung Progres dans les recherches sur le cancer, 54, 104–108. https://doi.org/10.1007/978-3-642-80997-2_8 - DOI
-
- Ritter, J., & Bielack, S. S. (2010). Osteosarcoma. Annals of Oncology, 21(Suppl 7), 320–325. https://doi.org/10.1093/annonc/mdq276 - DOI
-
- Geller, D. S., & Gorlick, R. (2010). Osteosarcoma: A review of diagnosis, management, and treatment strategies. Clinical Advances in Hematology & Oncology, 8(10), 705–718.
-
- Jones, K. B., Ferguson, P. C., Lam, B., Biau, D. J., Hopyan, S., Deheshi, B., Griffin, A. M., White, L. M., & Wunder, J. S. (2012). Effects of neoadjuvant chemotherapy on image-directed planning of surgical resection for distal femoral osteosarcoma. Journal of Bone and Joint Surgery. American Volume, 94(15), 1399–1405. https://doi.org/10.2106/JBJS.K.00971 - DOI
-
- Bielack, S., Carrle, D., & Casali, P. G. (2009). Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Annals of Oncology, 20(Suppl 4), 137–139. https://doi.org/10.1093/annonc/mdp154 - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials